GEN Exclusives

More »

GEN News Highlights

More »
Nov 28, 2007

Immunosyn Gets the Go-Ahead to Manufacture Its First Therapeutic for U.K. Clinical Trials

  • Biozyme Laboratories received approval to import base material and manufacture Immunosyn’s preclinical compound for use in clinical trials in the U.K. SF-1019 has been shown to reduce symptoms of a range of demyelinating conditions of the peripheral nervous system (PNS), according to Immunosyn.

    The license approvals currently granted by the MHRA include a ‘Manufacturer's Authorisation–Investigational Medicinal Products’ as well as ‘Manufacturer's/Importer's Licence’ for manufacturing investigational medicinal products for use in Phase I, II, and III studies. If a company successfully completes these trials it can apply for a full license to distribute throughout the EU.

    SF-1019 is part of a new class of therapeutics made from mammalian cells, Immunosyn reports. As an isolated compound, SF-1019 comprises low molecular weight lipo-peptides  Research suggests that it has additional developmental potential as a treatment for multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, reflex sympathetic dystrophy syndrome, and other autoimmune and neurological disorders.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?